Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study

Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study

BackgroundThe KEYNOTE-811 study exhibited promising preliminary results for HER2-positive metastasis gastric adenocarcinoma; however, long-term survival benefit remains to be determined.MethodsIn this single-center, controlled, retrospective study, patients with histologically confirmed HER2-positiv...

Full description

Bibliographic Details
Main Authors: Ting Deng, Danyang Li, Yuchong Yang, Feixue Wang, Ming Bai, Rui Liu, Hongli Li, Yi Ba
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
gastric/gastroesophageal adenocarcinoma
HER2-positive
anti-PD-1 antibody
trastuzumab
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1166040/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1166040/full

Similar Items